Takeda's QDENGA Dengue Vaccine Receives DCGI Approval for Use in India
Takeda Biopharmaceuticals India has received approval from the Drug Controller General of India (DCGI) for QDENGA, the country's first dengue vaccine for individuals aged 4 to 60. The vaccine protects against all four dengue virus serotypes without requiring prior exposure testing. Approved in 43 countries since 2022, QDENGA's authorization in India is based on extensive global clinical trials, including a Phase III study in Indian participants, demonstrating safety and sustained protection against dengue infection and hospitalization.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (72/100). Lens Score 49/100.
Outlets measured: moneycontrol, economictimes. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (70–74/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
economictimes broke this story on 20 Jul, 06:00 am. Other outlets followed.